Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
Titel:
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
Auteur:
Cremolini, Chiara Antoniotti, Carlotta Rossini, Daniele Lonardi, Sara Loupakis, Fotios Pietrantonio, Filippo Bordonaro, Roberto Latiano, Tiziana Pia Tamburini, Emiliano Santini, Daniele Passardi, Alessandro Marmorino, Federica Grande, Roberta Aprile, Giuseppe Zaniboni, Alberto Murgioni, Sabina Granetto, Cristina Buonadonna, Angela Moretto, Roberto Corallo, Salvatore Cordio, Stefano Antonuzzo, Lorenzo Tomasello, Gianluca Masi, Gianluca Ronzoni, Monica Di Donato, Samantha Carlomagno, Chiara Clavarezza, Matteo Ritorto, Giuliana Mambrini, Andrea Roselli, Mario Cupini, Samanta Mammoliti, Serafina Fenocchio, Elisabetta Corgna, Enrichetta Zagonel, Vittorina Fontanini, Gabriella Ugolini, Clara Boni, Luca Falcone, Alfredo